Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Xeruborbactam (QPX7728) and QPX2014 in Healthy Adults
NCT05072444Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bacterial infection comparing QPX7728 + QPX2014 with QPX2014 Alone (2 arms). Primary endpoints: Area under the plasma concentration versus time curve up to 9 days, Peak plasma Concentration up to 9 days and 4 more. Started Nov 2021; status: completed.
02
Drugs
xeruborbactamQPX2014
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05072444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05072444.